MIRA PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
MIRA$0.62+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, December 31, 2025 | 41,938,587 | $4,194 | $49,967,549 | $(39,580,206) | $10,391,537 |
| Stock-based compensation | — | — | 21,585 | — | 21,585 |
| Shares issued for vested RSU | 83,500 | 8 | 85,997 | — | 86,005 |
| Net loss | — | — | — | (1,150,152) | (1,150,152) |
| Balances, March 31, 2026 | 42,022,087 | $4,202 | $50,075,131 | $(40,730,358) | $9,348,975 |
| Stock-based compensation | — | — | 21,876 | — | 21,876 |
| Net loss | — | — | — | (1,208,534) | (1,208,534) |
| Balances, June 30, 2026 | 42,022,087 | $4,202 | $50,097,007 | $(41,938,892) | $8,162,317 |
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, December 31, 2024 | 16,560,852 | $1,656 | $31,335,815 | $(29,137,721) | $2,199,750 |
| Issuance of common stock under ATM, net of costs | 2,802 | 1 | 3,381 | — | 3,382 |
| Shares issued for vested RSUs | 250,000 | 25 | (25) | — | — |
| Stock-based compensation | — | — | 874,812 | — | 874,812 |
| Net loss | — | — | — | (1,783,779) | (1,783,779) |
| Balances, March 31, 2025 | 16,813,654 | $1,682 | $32,213,983 | $(30,921,500) | $1,294,165 |
| Issuance of common stock under ATM, net of costs | 321,486 | 32 | 323,808 | — | 323,840 |
| Shares issued for vested RSUs | 250,000 | 25 | (25) | — | — |
| Stock-based compensation | — | — | 489,566 | — | 489,566 |
| Net loss | — | — | — | (1,537,712) | (1,537,712) |
| Balances, June 30, 2025 | 17,385,140 | $1,739 | $33,027,332 | $(32,459,212) | $569,859 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.